Tumor-treating fields elicit a conditional vulnerability to ionizing radiation via the downregulation of BRCA1 signaling and reduced DNA double-strand break repair capacity in non-small cell lung cancer cell lines
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
The use of tumor-treating fields (TTFields) has revolutionized the treatment of recurrent and newly diagnosed glioblastoma (GBM). TTFields are low-intensity, intermediate frequency, alternating electric fields that are applied to tumor regions and cells using non-invasive arrays. The predominant mechanism by which TTFields are thought to kill tumor cells is the disruption of mitosis. Using five non-small cell lung cancer (NSCLC) cell lines we found that there is a variable response in cell proliferation and cell killing between these NSCLC cell lines that was independent of p53 status. TTFields treatment increased the G2/M population, with a concomitant reduction in S-phase cells followed by the appearance of a sub-G1 population indicative of apoptosis. Temporal changes in gene expression during TTFields exposure was evaluated to identify molecular signaling changes underlying the differential TTFields response. The most differentially expressed genes were associated with the cell cycle and cell proliferation pathways. However, the expression of genes found within the BRCA1 DNA-damage response were significantly downregulated (P<0.05) during TTFields treatment. DNA double-strand break (DSB) repair foci increased when cells were exposed to TTFields as did the appearance of chromatid-type aberrations, suggesting an interphase mechanism responsible for cell death involving DNA repair. Exposing cells to TTFields immediately following ionizing radiation resulted in increased chromatid aberrations and a reduced capacity to repair DNA DSBs, which were likely responsible for at least a portion of the enhanced cell killing seen with the combination. These findings suggest that TTFields induce a state of ‘BRCAness’ leading to a conditional susceptibility resulting in enhanced sensitivity to ionizing radiation and provides a strong rationale for the use of TTFields as a combined modality therapy with radiation or other DNA-damaging agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stupp, R., Taillibert, S., Kanner, A. A., Kesari, S., Steinberg, D. M., Toms, S. A., Taylor, L. P., Lieberman, F., Silvani, A., Fink, K. L., et al. (2015) · JAMA · doi:10.1001/jama.2015.16669 · Cited by 1,259
Analysis of drug combinations: current methodological landscape
Foucquier, J., & Guedj, M. (2015) · Pharmacology Research & Perspectives · doi:10.1002/prp2.149 · Cited by 1,115
Methylated lysine 79 of histone H3 targets 53BP1 to DNA double-strand breaks
Huyen, Y., Zgheib, O., DiTullio Jr, R. A., Gorgoulis, V. G., Zacharatos, P., Petty, T. J., Sheston, E. A., Mellert, H. S., Stavridi, E. S., & Halazonetis, T. D. (2004) · Nature · doi:10.1038/nature03114 · Cited by 884
Disruption of cancer cell replication by alternating electric fields
Kirson, E. D., Gurvich, Z., Schneiderman, R., Dekel, E., Itzhaki, A., Wasserman, Y., Schatzberger, R., & Palti, Y. (2004) · Cancer research · doi:10.1158/0008-5472.can-04-0083 · Cited by 827
Giladi, M., Schneiderman, R. S., Voloshin, T., Porat, Y., Munster, M., Blat, R., Sherbo, S., Bomzon, Z., Urman, N., Itzhaki, A., et al. (2015) · Scientific Reports · doi:10.1038/srep18046 · Cited by 327 · cited 2×
“TTFields are known to decrease cellular proliferation and induce abortive apoptosis in dividing cancer cells across a variety of human and rodent tumor cell lines.(13) Prevention of proper formation of the mitotic spindle apparatus and the activation of the mitotic spindle checkpoint has been proposed as the mechanism…”
BackgroundChemical combination effects predict connectivity in biological systems
Lehár, J., Zimmermann, G. R., Krueger, A. S., Molnar, R. A., Ledell, J. T., Heilbut, A. M., Short, G. F., Giusti, L. C., Nolan, G. P., Magid, O. A., et al. (2007) · Molecular Systems Biology · doi:10.1038/msb4100116 · Cited by 275
Kirson, E. D., Schneiderman, R. S., Dbalý, V., Tovaryš, F., Vymazal, J., Itzhaki, A., Mordechovich, D., Gurvich, Z., Shmueli, E., Goldsher, D., et al. (2009) · BMC Medical Physics · doi:10.1186/1756-6649-9-1 · Cited by 224 · cited 1×
“In the context of cancer therapy, TTFields has been shown to enhance the efficacy of numerous chemotherapeutic agents when used in combination such as paclitaxel and doxorubicin in multidrug-resistant cancer cells—without increasing the intracellular accumulation of the drugs;(17) decreased cellular proliferation, sur…”
BackgroundTumor Treating Fields Perturb the Localization of Septins and Cause Aberrant Mitotic Exit
Gera, N., Yang, A., Holtzman, T. S., Lee, S. X., Wong, E. T., & Swanson, K. D. (2015) · PLOS ONE · doi:10.1371/journal.pone.0125269 · Cited by 217 · cited 3×
“Earlier, Gera et al.16 showed that TTFields sensitivity is dependent on p53 status in colon cancer cells; however, cell proliferation and survival results from our study and recent studies by others13,22 suggest that TTFields effects are independent of p53 status (Table 1 and Figure 1).”
BackgroundResultInfluentialTumor treating fields: A new frontier in cancer therapy
Davies, A. M., Weinberg, U., & Palti, Y. (2013) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12112 · Cited by 193
Alternating electric fields (TTFields) inhibit metastatic spread of solid tumors to the lungs
Kirson, E. D., Giladi, M., Gurvich, Z., Itzhaki, A., Mordechovich, D., Schneiderman, R. S., Wasserman, Y., Ryffel, B., Goldsher, D., & Palti, Y. (2009) · Clinical & Experimental Metastasis · doi:10.1007/s10585-009-9262-y · Cited by 171 · cited 1×
“In addition to its efficacy in treating primary tumors, TTFields have also demonstrated the ability to prevent or delay metastasis in animal models, a process likely resulting from enhancement of the antitumor immune response.(20) Furthermore, it was recently shown that TTFields enhanced the efficacy of radiation trea…”
BackgroundGiladi, M., Schneiderman, R. S., Porat, Y., Munster, M., Itzhaki, A., Mordechovich, D., Cahal, S., Kirson, E. D., Weinberg, U., & Palti, Y. (2014) · Pancreatology · doi:10.1016/j.pan.2013.11.009 · Cited by 98 · cited 1×
“Previous studies have demonstrated that TTFields exhibit optimal effectiveness in a cell line-specific manner.(6,18,22) To determine the optimal frequency to maximize growth inhibition, cells were treated at different frequencies ranging from 100 to 300 kHz.”
Background
Cited by
Tumour treating fields therapy for glioblastoma: current advances and future directions
Rominiyi, O., Vanderlinden, A., Clenton, S. J., Bridgewater, C., Al-Tamimi, Y., & Collis, S. J. (2021) · British Journal of Cancer · doi:10.1038/s41416-020-01136-5 · Cited by 315
Glioblastoma Therapy: Past, Present and Future
Obrador, E., Moreno-Murciano, P., Oriol-Caballo, M., López-Blanch, R., Pineda, B., Gutiérrez-Arroyo, J., Loras, A., Gonzalez-Bonet, L., Martinez-Cadenas, C., Estrela, J., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052529 · Cited by 271
Tumor treating fields increases membrane permeability in glioblastoma cells
Chang, E., Patel, C. B., Pohling, C., Young, C., Song, J., Flores, T. A., Zeng, Y., Joubert, L.-M., Arami, H., Natarajan, A., et al. (2018) · Cell Death Discovery · doi:10.1038/s41420-018-0130-x · Cited by 137
Shteingauz, A., Porat, Y., Voloshin, T., Schneiderman, R. S., Munster, M., Zeevi, E., Kaynan, N., Gotlib, K., Giladi, M., Kirson, E. D., et al. (2018) · Cell Death & Disease · doi:10.1038/s41419-018-1085-9 · Cited by 107
Alternating Electric Fields (TTFields) Activate Cav1.2 Channels in Human Glioblastoma Cells
Neuhaus, E., Zirjacks, L., Ganser, K., Klumpp, L., Schüler, U., Zips, D., Eckert, F., & Huber, S. M. (2019) · Cancers · doi:10.3390/cancers11010110 · Cited by 63
“The latter probably results from TTFields-mediated delay in DNA double strand break repair [23] possibly via downregulation of BRCA1 signaling [14].”
Background
Metadata
- Authors
- Karanam, N. K., Srinivasan, K., Ding, L., Sishc, B., Saha, D., & Story, M. D.
- Venue
- Cell Death & Disease
- Published
- 2017-03-30
- Volume
- 8
- Issue
- 3
- Pages
- e2711-e2711
- ISSN
- 2041-4889 (ISSN-L)
- OpenAlex
- W2597844539
- Cited by
- 136
- References
- 11
- FWCI
- 3.69
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.